Kornimate/medical-research-clean huggingface dataset:
efficacy study of continuous intraarticular infusion in patients undergoing arthroscopic knee and shoulder operations

Conditions: ACL Repair; Meniscectomy; Bankart Repair

Summary: the aim of this study is to determine whether the continuous intraarticular infusion of local anesthetics in the postoperative period can improve analgesia and patients satisfaction after knee and shoulder arthroscopy.

we propose to evaluate the long-term efficacy of the continuous intraarticular delivery of local anesthetics via a disposable, self-regulated donjoy pain control infusion pump. patients will be randomly assigned to receive either an intra-articular infusion of bupivacaine 0.125%, or saline delivered at a rate of 5 ml/hr for 48 hours by a donjoy® pain control infusion pump. patients will receive a femoral block (fnb) and a sciatic block (snb) for knee arthroscopy or an interscalene block (inb) for shoulder arthroscopy prior to surgery. after the operation, patients will receive morphine via a patient controlled analgesia (pca) pump for pain control. the patient will be admitted overnight to a care unit, with the pca discontinued at discharge or 24 hours, whichever is earlier. if clinically indicated, the pca may be extended at the discretion of the pain team. upon discharge and during the 48 hour study period the patient will receive oral oxycodone and acetaminophen. the patient and their family will remove the donjoy® pain control infusion pump 48 hours after the surgery.

Eligibility criteria:
inclusion criteria: * children between the ages of 11 and 19 years old. * knee and shoulder arthroscopy procedures exclusion criteria: * contraindications to femoral-interscalene nerve block * conditions that affect the proper evaluation of pain and side effects. * intake of nsaids or opioids in the 12 hours prior to the operation * allergy to study medications

Keywords: pain control intra-articular pain control device acl repair bankart repair
the excel registry of patients requiring ecmo

Conditions: Critically Ill; Acute Respiratory Failure; Acute Heart Failure; Cardiac Arrest

Summary: ecmo is associated with significant costs, risks and requires specialist training and expertise. excel is a novel, high-quality, detailed prospective registry of patients requiring ecmo in australia and new zealand. the registry provides information on patient selection, complications, costs and patient reported outcome measures. excel uses the theoretical domains framework to identify evidence-practice gaps and explore barriers and enablers to tailor implementation of evidence

the aim of excel is to generate a bi-national multidisciplinary network of integrated care for patients suffering acute cardiac or respiratory failure or cardiac arrest requiring extracorporeal membrane oxygenation (ecmo) to monitor long term outcomes and identify best practice. each year around 130,000 australians and new zealanders are admitted to an intensive care unit (icu). the sickest patients in the icu who have severe failure of the heart or lungs may require an external machine to oxygenate their blood in addition to a mechanical ventilator. this intervention, called extracorporeal membrane oxygenation (ecmo), involves circulating all of the patient's blood through large cannulae to external machinery every minute. it has the capability of completely replacing a non-functioning heart or lungs for days to weeks on end. these critically ill patients who require ecmo are the sickest in the hospital with only 42% hospital survival. the use of ecmo has doubled in australia and new zealand and globally over five years, and in the usa has increased by 433%. the use of ecmo is associated with significant costs and risks, and it requires specialist training and expertise. in order to prepare for the organisation of these complex interventions in the icu across regions, the investigators need to have accurate data on patients undergoing ecmo. the investigators monitor and review current practice in ecmo services by providing robust binational registry data to service providers and clinicians with a closed-loop feedback system. excel explores barriers and enablers to evidence-based care in ecmo services and providing a platform to embed clinical trials. the investigators will translate findings with greater capacity, reach, and impact to drive measureable change in practice and improve patient-centred outcomes. the excel partnership represents a novel, coordinated effort to create a high-quality, detailed, prospective registry of patients requiring ecmo at ecmo centres. a tailored, detailed ecmo registry (excel) can be used to address specific safety concerns, clinical questions and process of care issues. as a result, excel can be designed and implemented to answer new investigator-initiated, hypothesis-driven clinical questions.

Eligibility criteria:
inclusion criteria: * patients admitted to adult hospitals and receive ecmo in australia and new zealand nil exclusion criteria

Keywords: intensive care critical care extracorporeal membrane oxygenation extracorporeal life support
performance of white light, nbi and iodine staining endoscopy in the diagnosis of esophageal lesions

Conditions: Mild Dysplasia of Esophagus; Moderate Dysplasia of Esophagus; Severe Dysplasia of Esophagus; Carcinoma in Situ of Esophagus; Esophageal Squamous Cell Carcinoma

Summary: the investigators aim to evaluate the performance of narrow band imaging (nbi) endoscopy in esophageal squamous cell carcinoma (escc) screening, as compared to the currently used white light endoscopy (wle) and lugol's iodine staining endoscopy (ise). nbi is a simple, safe and non-invasive technique, which can provide real-time optical staining for suspicious lesions. this trial is designated to enroll 10000 participants from five centers located in different regions (north, west and south) in china, which would provide real-world evidence for the recommendation of endoscopic diagnostic technique used in escc screening projects.


Eligibility criteria:
inclusion criteria: * patients seek for endoscopic examinations at the endoscopy center in any of the five hospitals included in this study * aged 45-69 years * have entire esophagus * provide written informed consent and leave personal identification and contact information exclusion criteria: * have contraindications to endoscopic examination (including but not limited to severe arrhythmia, myocardial infarction, heart failure, hemiplegia, asthma, severe hypertension (≥ 180 / 110mmhg), psychosis, etc ) * have a history of drug allergy * have a history of upper gastrointestinal surgery * have a history of radiotherapy or chemotherapy

Keywords: esophageal squamous cell carcinoma population-level screening narrow band imaging iodine staining sensitivity and specificity
a retrospective study of egfr-tkis,gefitinib, erlotinib and osimertinib in nsclc patients treatment

Conditions: Non-small Cell Lung Cancer (NSCLC); EGFR-TKI Resistant Mutation; EGFR-TKI Sensitizing Mutation; Germline Mutations; Somatic Mutation

Summary: for patients of advanced nsclc (non small cell lung cancer) , individualized cancer therapy has been widely accepted since the success of crizotinib administration based on eml4-alk fusion gene detection and gefitinib and erlotinib administration based on egfr-tkis sensitive mutations.from clinical points of view ,individual differences often occur between different patients, leading diverse effect in adr and drug effect.meanwhile ,the drug effect and adverse drug reaction was significantly influenced by the pharmacokinetic factors and pharmacodynamic factors.in this research ,we try to establish a more sensitive method to detect sensitive mutations in plasma and discover the correlation between somatic and germline mutations , trough concentration and egfr-tki drug effect, the association between adme-associated snp ,trough concentration and egfr-tki adverse effect .furthermore, in vivo and in vitro research is also crucial for rational explanation for these clinical phenomenon.

the adme-associated snps included are cyp3a4,cyp3a4,cyp1a1,cyp2d6, abcb1,abcg2 and so on .the somatic mutations included are egfr ,k-ras ,alk and so on

Eligibility criteria:
inclusion criteria: the main patient entry criteria included: age≥ 18 years ; histologically and cytologically proved nsclc; eastern cooperative oncology group performance status (ecog ps)≤2; adequate hematological , renal, and hepatic functions. exclusion criteria: uncontrolled systemic disease ,any evidence of clinically active interstitial lung diseases, and other chemotherapy at the time of inclusion. the protocol was approved by the ethical committee of cancer center of sun yat-sen university (ccsu), and written informed consent was obtained form each patient.

Keywords: non-small cell lung cancer (nsclc); egfr-tki; pharmacogenetics; precision medicine somatic mutations ,germline mutations;
mental health in primary care

Conditions: Depression, Anxiety; Suicide; Drug Use

Summary: the goal of this study is to evaluate in an effectiveness-implementation type i hybrid trial, an enhanced version of ehealth familias unidas for reducing depressive, anxious symptoms and suicide behavior in hispanic youth. the study will use a randomized rollout design with 18 pediatric primary care clinics in the south florida area.


Eligibility criteria:
inclusion criteria: 1. female and male adolescents, who self-identify as hispanic (or latino(a)) 2. adolescent between the ages of 12 - 16 years 3. adolescent living with an adult primary caregiver who is willing to participate 4. families must have broadband internet access on a device, including (but not limited to) a smartphone, ipad, tablet, computer at their home or other location (e.g., school, library, etc.) 5. families screening positive on poor family communication (a score of less than 75 on the communication measure; see measures) or youth reporting elevated depressive or anxiety symptom scores (defined as 70 to 90 on the k-cat) or a history of suicide behavior (ideation or attempts). exclusion criteria: * families reporting plans to move out of the south florida area during the study period.

Keywords: effectiveness-implementation type 1 hybrid trial latinx mental health in primary care latinx adolescent ehealth intervention familias unidas intervention sustainment parent-centered family functioning sexual risk behavior
prophylactic piperacillin/tazobactam in hematopoietic stem cell transplantation

Conditions: Neutropenia; Hematopoietic Stem Cell Transplantation

Summary: neutropenia is very common in patients received hematopoietic stem cell transplantation, with median duration of about 14 days. almost all neutropenia will suffer from febrile without prophylactic antibiotics. idsa recommended fluoroquinolones as prophylaxis in neutropenia patients of high risks, while in china, major pathogens possess high resistance to fluoroquinolones. it is not clear whether prophylaxis is of benefit, nor the appropriate prophylaxis regimen. the current study will evaluate the three different regimen: 1. no prophylaxic antibiotic 2. piperacillin as prophylaxis for neutropenia patients. piperacillin has anti-pseudomonas activity. 3. piperacillin/tazobactam as prophylaxis for neutropenia patients. piperacillin/tazobactam has highest susceptibility rate among common anti-pseudomonas antibiotics.

1. swab culture (skin, pharyngeal, nasal, anus) when administered into laminar flow room after transplantation. 2. randomize the neutropenia patients into 3 groups. 3. receive 3 regimen. 4. full record of clinical data, including background diseases, previous antibiotics within 90 days, febrile or not at the toc. 5. for patients developed febrile, imipenem will be prescribed, even if the patient received no prophylaxis. at the same time, the follow-up ended.

Eligibility criteria:
inclusion criteria: * age 13-65 years * received autologous or allogeneic hematopoietic stem cell transplantation. * ecog score 0-1. * icf is available. exclusion criteria: * allergic to any therapy drug. * documented infection before neutropenia. * renal dysfunction. * suffering from central nervous system or mental disease.
efficacy of modified constraint-induced movement therapy in children with brain damage

Conditions: Brain Damage; Cerebral Palsy; Traumatic Brain Damage

Summary: this research centers on the comparison of the immediate efficacy (right after therapy) and the maintained efficacy (3 months and 6 months) between "modified constraint-induced movement therapy" (mcimt) group and control group at different age.

"modified constraint-induced movement therapy" is one of the most recent treatments for children with brain damage. this well-designed and follow-up rct study compared home-based cit with a control intervention (traditional rehabilitation, tr) by combining kinematic analysis and clinical evaluation, which is possible to examine whether functional improvement is accompanied by a change in motor control. we hypothesized that home-based cit would induce better motor control strategies (shorter rt, mt, lesser mus, mga, and pmga, and larger peak velocity (pv)) for greater functional gains than tr. furthermore, the beneficial effects would be maintained at 3 and 6 months of follow-up. findings of this study allow clinicians to understand the underlying motor control changes for functional improvement after home-based cit.

Eligibility criteria:
inclusion criteria: 1. development learned-nonuse 2. age range 4y/o-15y/o 3. wrist ext 10˚, mp j't ext 10˚ in affected u/e 4. can fallow up the simple instruction 5. modified ashworth scale ≦2 6. pediatric motor activity log ≦2.5 (average) exclusion criteria: 1. related muscle skeleton surgery 2. selective dorsal rhizotomy 3. botulinum toxin in 6 months 4. visual perception impaired 5. hearing perception impaired 6. balance ability impaired (in constrained)

Keywords: brain damage constraint induced movement therapy kinematic function outcome quality of life
trufreeze cryotherapy central airway disease

Conditions: Airway Obstruction

Summary: rationale: spray cryotherapy (sct) using liquid nitrogen has been safely and effectively used in the esophagus, airways and pleura. treatment with sct for central airway stenosis may provide an effective, and more durable and perhaps safer alternative to the current therapeutic modalities. objectives: 1. to investigate the feasibility of using spray cryotherapy (sct) for the treatment of malignant and benign central airway disease. 2. to investigate the safety of using spray cryotherapy (sct) for the treatment of malignant and benign central airway disease. 3. to investigate the efficacy of using spray cryotherapy (sct) for the treatment of malignant and benign central airway disease. study design: this study will be a prospective, single arm, open label intervention study performed at the university medical center groningen, the netherlands study population: the study population exists of 25 patients with malignant or benign central airway disease. patients in which current treatment options are regarded to be suboptimal can be included in the study. intervention: trufreeze spray cryotherapy main study parameter: feasibility is defined as being able to apply the sct as planned in one, or more bronchoscopies according to the instructions for use (ifu). secondary study parameters: safety will be assessed by capturing all adverse events (aes) that occur 1) during the sct procedure, and 2) all aes that occur until hospital discharge. efficacy will be measured using 1) patient reported outcomes (questionnaires), 2) percentage improvement in airway stenosis, 3) durability of treatment effect, 4) need to re-intervene with other therapies because of treatment failure. nature and extent of the burden, risks and benefit associated with participation. patients that will be recruited and participate in this prospective clinical trial have a severe central airway disease which is highly symptomatic for which current available therapies are either very difficult to perform, are hazardous, have no real benefit, or just simply not available yet. the current treatment risks of this patient group are high, especially in the patients where the airway patency is at risk. the main additional risk associated with the use of sct is the occurrence of a pneumothorax. patients participating will adhere to their current medical care, with the one addition of a voluntary follow-up bronchoscopy after sct.


Eligibility criteria:
inclusion criterium: 1. presence of malignant or benign central airway disease where current treatment options are regarded to be suboptimal. exclusion criteria: 1. patient has an inability to tolerate bronchoscopy under general anaesthesia. 2. compromised tissue (significant ulceration or mucosal break in the ablation area, any procedure or pre-existing condition has significantly reduced tissue strength or has significantly reduced the elasticity of the ablation area). 3. airway diameter causing an anatomical flow resistance inhibiting n2 gas evacuation (endotracheal tube or equivalent \<8.5mm will be excluded).

Keywords: spray cryotherapy
antipsychotic medicine and metabolic syndrome

Conditions: Metabolic Syndrome

Summary: the purpose of the study is to determine whether antipsychotic treatment is influence psychiatric patients due to endocrine and metabolic status and a quality of life. the investigators expect, that 30-50% of patients will show pharmacon - gene induced weight gain (\> 7% of initial bodyweight) while the rest of patients will maintain unaltered bodyweight.

the primary aim of this study is to investigate status of neuro-and enteroendocrine axes with focus on beta - cell function in relation to insulin resistance, lipid profile abnormalities and inflammations adipokins in patients during treatment with antipsychotics (ap) in relation to weight gain. the second aim is to evaluate the connection between weight gain and patients´ own perception of their quality of life and health.

Eligibility criteria:
inclusion criteria: * gender : male * age: 18-45 * treatment with minimum one antipsychotic drug (ap) * ethnicity: caucasians * consent given to take part in the project exclusion criteria: one criteria is sufficient to exclude patients from the study: * compliance problems * unable to read, write and talk danish * patients with major lung-,heart-, lever- and kidney problems * patients with diagnose and treatment for diabetes 1 and 2 * patients taking cholesterol-reducing, weight-reducing and antihypertensive medication * patients with abuse of alcohol or drugs * patients who are under duress § * patients who have been mentally ill for more than 15 years * patients with diagnosis/treatment for niddm/iddm

Keywords: metabolic syndrome weight gain antipsychotic drugs metabolic syndrome and treatment with antipsychotic drugs
associations of plasma vanadium concentrations with gestational diabetes mellitus

Conditions: Gestational Diabetes

Summary: background: vanadium compounds have been shown to exert insulin-mimetic effects and thereby control glucose homeostasis. however, studies regarding the levels of vanadium and gestational diabetes mellitus (gdm) are limited and have inconsistent outcomes. objective: the aim of this study was to investigate the association of plasma vanadium concentrations with gestational diabetes mellitus (gdm). design: a hospital-based case-control study was carried out in urban wuhan, china from august 2012 to april 2015. pregnant women who screened for gdm at the outpatient clinics of the department of endocrinology, tongji hospital were invited to participant in the study. the inclusion criteria were as follows: 1) age ≥ 20 and ≤ 43 years; 2) gestational age at gdm screening ≥ 24 weeks; 3) singleton pregnancy. the investigators excluded women who met any of the following items: history of diabetes (including but not limited to gdm), cardiovascular disease, cancer or other systemic diseases; pharmacologic treatment or dietary supplement use that might influence glucose or lipids metabolism; accompanied by other pregnancy complications; incomplete basic information. the diagnosis of gdm can be made if one or more glucose values are above the cut points of 5.1, 10.0 and 8.5 mmol/l at fasting, 1 and 2 h during a 75-gram oral glucose tolerance test (ogtt). controls were randomly selected and individually matched to cases by age (± 2 years), gestational age (± 2 weeks) and parity. finally, 252 gdm cases and 252 matched controls were selected in this study. all participants gave written informed consent before enrolling in the study. fasting blood samples (≥ 8 h overnight fasting) were collected using anticoagulant tubes and centrifuged at 3000 rpm for 5 min. plasma were separated from blood cells and stored at -80 ℃ for further assay. plasma vanadium concentrations were measured using inductively coupled plasma mass spectrometry. conditional logistic regression and restricted cubic spline model were used to evaluate the associations between plasma vanadium and odds of gdm.


Eligibility criteria:
inclusion criteria: * age ≥ 20 and ≤ 43 years; * gestational age at gdm screening ≥ 24 weeks; * singleton pregnancy; exclusion criteria: * history of diabetes (including but not limited to gdm), cardiovascular disease, cancer or other systemic diseases; * history of receiving pharmacological treatment known to affect glucose metabolism; * incomplete basic information.

Keywords: vanadium gestational diabetes mellitus
multi-omics based prediction of treatment response to immunotherapy combined with chemotherapy in advanced gastric/gastroesophageal junction cancer.

Conditions: Advanced Gastric Carcinoma; Advanced Gastroesophageal Junction Adenocarcinoma

Summary: in this project, based on the information of advanced gastric/gastroesophageal junction cancer in evolution under immunotherapy combined with chemotherapy treatment, we will integrate multi-omics dynamic data to identify essential features that correlate to therapeutic effects of immunotherapy therapy, screen potential molecular markers/dominant microbiota for predicting the efficacy of immunotherapy and establish a multimodal predictive model for patients that benefit from immunotherapy. our project could provide evidence to predict response to immunotherapy for patients with advanced gastric/gastroesophageal junction cancer and potentially optimize the clinical decision-making about therapy for advanced gastric/gastroesophageal junction cancer.

main objective: to extract and identify multi omics information tags related to the efficacy of immunotherapy for advanced gastric / gastroesophageal junction cancer secondary objective: to construct and validate the efficacy prediction model of chemotherapy combined with immunotherapy for gastric cancer, in order to optimize the scheme decision of advanced gastric cancer treatment exploratory purpose: to screen potential molecular markers / dominant flora for predicting the efficacy of immunotherapy in patients with advanced gastric / gastroesophageal junction cancer

Eligibility criteria:
inclusion criteria： * patients with gastric or gastroesophageal junction adenocarcinoma confirmed by pathology and with advanced or metastatic disease that cannot be resected * her2 negative * not received any anti-tumor treatment before. * after evaluation, the treatment plan is chemotherapy combined with immunotherapy. * aged 18 to 75 years old, gender is not limited. * expected survival time is greater than or equal to 3 months. exclusion criteria： * patients with malignant tumors other than gastric cancer or those with tumors metastasized to the stomach from other sites. * patients who have previously received anti-tumor treatments such as surgery, radiotherapy and chemotherapy, targeted therapy or immunotherapy. * patients with severe infections. * those with a history of mental illness cannot cooperate with the research. * patients with severe heart, liver, kidney and other diseases. * pregnant or lactating patients. * her2 positive.

Keywords: advanced gastric carcinoma advanced gastroesophageal junction adenocarcinoma chemotherapy combined with immunotherapy efficacy prediction